Evotec and Exscientia Initiate Human Clinical Trials of their Novel Immuno-Oncology Drug
Shots:
- The companies initiate the clinical trial of A2a receptor antagonist- co-developed by Exscientia and Evotec utilizing Exscientia's AI-design platform- Centaur Chemist
- Exscientia will lead the clinical development phase of the molecule and Evotec retains co-ownership rights throughout clinical development
- The A2a receptor is currently in development for adult patients with advanced solid tumors and has the potential to show high selectivity for the targeted receptor
Ref: Evotec | Image: Wikipedia
Click here to read the full press release
Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com
